Revision of Patent Term Extension and Adjustment Provisions Relating to Appellate Review and Information Disclosure Statements, 18990-18995 [2011-8275]
Download as PDF
erowe on DSK5CLS3C1PROD with PROPOSALS-1
18990
Federal Register / Vol. 76, No. 66 / Wednesday, April 6, 2011 / Proposed Rules
association determines is appropriate,
taking into consideration the size of an
issuer and any other relevant factors.
(2) Authority to engage compensation
consultants, independent legal counsel
and other compensation advisers. The
compensation committee of a listed
issuer, in its capacity as a committee of
the board of directors, may, in its sole
discretion, retain or obtain the advice of
a compensation consultant,
independent legal counsel or other
adviser. The compensation committee
shall be directly responsible for the
appointment, compensation and
oversight of the work of any
compensation consultant, independent
legal counsel and other adviser to the
compensation committee. Nothing in
this paragraph (b) shall be construed:
(i) To require the compensation
committee to implement or act
consistently with the advice or
recommendations of the compensation
consultant, independent legal counsel
or other adviser to the compensation
committee; or
(ii) To affect the ability or obligation
of a compensation committee to exercise
its own judgment in fulfillment of the
duties of the compensation committee.
(3) Funding. Each listed issuer must
provide for appropriate funding, as
determined by the compensation
committee, in its capacity as a
committee of the board of directors, for
payment of reasonable compensation to
a compensation consultant,
independent legal counsel or any other
adviser to the compensation committee.
(4) Independence of compensation
consultants and other advisers. The
compensation committee of a listed
issuer may select a compensation
consultant, legal counsel, or other
adviser to the compensation committee
only after taking into consideration the
following factors, as well as any other
factors identified by the relevant
national securities exchange or national
securities association in its listing
standards:
(i) The provision of other services to
the issuer by the person that employs
the compensation consultant, legal
counsel or other adviser;
(ii) The amount of fees received from
the issuer by the person that employs
the compensation consultant, legal
counsel or other adviser, as a percentage
of the total revenue of the person that
employs the compensation consultant,
legal counsel, or other adviser;
(iii) The policies and procedures of
the person that employs the
compensation consultant, legal counsel
or other adviser that are designed to
prevent conflicts of interest;
VerDate Mar<15>2010
15:34 Apr 05, 2011
Jkt 223001
(iv) Any business or personal
relationship of the compensation
consultant, legal counsel, or other
adviser with a member of the
compensation committee; and
(v) Any stock of the issuer owned by
the compensation consultant, legal
counsel or other adviser.
(5) General exemptions. (i) The
national securities exchanges and
national securities associations,
pursuant to section 19(b) of the Act (15
U.S.C. 78s(b)) and the rules thereunder,
may exempt from the requirements of
this section certain categories of issuers,
as the national securities exchange or
national securities association
determines is appropriate, taking into
consideration the potential impact of
such requirements on smaller reporting
issuers.
(ii) The requirements of this section
shall not apply to any controlled
company.
(iii) The listing of a security futures
product cleared by a clearing agency
that is registered pursuant to section
17A of the Act (15 U.S.C. 78q–1) or that
is exempt from the registration
requirements of section 17A(b)(7)(A) (15
U.S.C. 78q–1(b)(7)(A)) is not subject to
the requirements of this section.
(iv) The listing of a standardized
option, as defined in § 240.9b–1(a)(4),
issued by a clearing agency that is
registered pursuant to section 17A of the
Act (15 U.S.C. 78q–1) is not subject to
the requirements of this section.
(c) Definitions. Unless the context
otherwise requires, all terms used in
this section have the same meaning as
in the Act. In addition, unless the
context otherwise requires, the
following definitions apply for purposes
of this section:
(1) In the case of foreign private
issuers with a two-tier board system, the
term board of directors means the
supervisory or non-management board.
(2) The term controlled company
means an issuer:
(i) That is listed on a national
securities exchange or by a national
securities association; and
(ii) That holds an election for the
board of directors of the issuer in which
more than 50 percent of the voting
power is held by an individual, a group
or another issuer.
(3) The terms listed and listing refer
to equity securities listed on a national
securities exchange or listed in an
automated inter-dealer quotation system
of a national securities association or to
issuers of such securities.
(4) The term open-end management
investment company means an openend company, as defined by Section
5(a)(1) of the Investment Company Act
PO 00000
Frm 00037
Fmt 4702
Sfmt 4702
of 1940 (15 U.S.C. 80a–5(a)(1)), that is
registered under that Act.
Dated: March 30, 2011.
Elizabeth M. Murphy,
Secretary.
[FR Doc. 2011–7948 Filed 4–5–11; 8:45 am]
BILLING CODE 8011–01–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
37 CFR Part 1
[Docket No.: PTO–P–2011–0014]
RIN 0651–AC56
Revision of Patent Term Extension and
Adjustment Provisions Relating to
Appellate Review and Information
Disclosure Statements
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of proposed rulemaking.
AGENCY:
The United States Patent and
Trademark Office (Office) is proposing
to revise the patent term adjustment and
extension provisions of the rules of
practice in patent cases. The patent term
adjustment provisions of the American
Inventors Protection Act of 1999 (AIPA)
and the patent term extension
provisions of the Uruguay Round
Agreements Act (URAA) each provide
for patent term extension or adjustment
if the issuance of the patent was delayed
due to appellate review by the Board of
Patent Appeals and Interferences (BPAI)
or by a Federal court and the patent was
issued pursuant to or under a decision
in the review reversing an adverse
determination of patentability. The
Office is proposing to change the rules
of practice to indicate that in most
circumstances an examiner reopening
prosecution of the application after a
notice of appeal has been filed will be
considered a decision in the review
reversing an adverse determination of
patentability for purposes of patent term
adjustment or extension purposes.
Therefore, in such situations, patentees
would be entitled to patent term
extension or adjustment. In addition,
the AIPA provides for a reduction of any
patent term adjustment if the applicant
failed to engage in reasonable efforts to
conclude prosecution of the application.
The Office is also proposing to change
the rules of practice pertaining to the
reduction of patent term adjustment for
applicant delays to exclude information
disclosure statements resulting from the
citation of information by a foreign
patent office in a counterpart
SUMMARY:
E:\FR\FM\06APP1.SGM
06APP1
Federal Register / Vol. 76, No. 66 / Wednesday, April 6, 2011 / Proposed Rules
erowe on DSK5CLS3C1PROD with PROPOSALS-1
application that are promptly filed with
the Office. For example, under the
proposed rule, there would not be a
reduction of patent term adjustment in
the following situations: When
applicant promptly submits a reference
in an information disclosure statement
after the mailing of a notice of
allowance if the reference was cited by
the Office in another application, or
when applicant promptly submits a
copy of an Office communication (e.g.,
an Office action) in an information
disclosure statement after the mailing of
a notice of allowance if the Office
communication was issued by the Office
in another application or by a foreign
patent office in a counterpart foreign
application.
Section
532(a) of the URAA (Pub. L. 103–465,
108 Stat. 4809 (1994)) amended 35
U.S.C. 154 to provide that the term of
a patent ends on the date that is twenty
years from the filing date of the
application, or the earliest filing date for
which a benefit is claimed under 35
U.S.C. 120, 121, or 365(c). The URAA
also contained provisions, codified at 35
U.S.C. 154(b), for patent term extension
due to certain examination delays.
Under the patent term extension
provisions of 35 U.S.C. 154(b) as
amended by the URAA, an applicant is
entitled to patent term extension for
delays due to interference, secrecy
order, or successful appellate review.
See 35 U.S.C. 154(b) (1995). The Office
implemented the patent term extension
DATES: Written comments must be
provisions of the URAA in a final rule
received on or before May 6, 2011. No
published in April of 1995. See Changes
public hearing will be held.
to Implement 20-Year Patent Term and
ADDRESSES: Comments concerning this
Provisional Applications, 60 FR 20195
proposed rule should be sent by
(Apr. 25, 1995) (twenty-year patent term
electronic mail message over the
final rule).
Internet addressed to
The AIPA (Pub. L. 106–113, 113 Stat.
AC56.comments@uspto.gov. Comments
1501, 1501A–552 through 1501A–591
may also be submitted by mail
(1999)) further amended 35 U.S.C.
addressed to: Mail Stop Comments—
154(b) to include additional bases for
Patents, Commissioner for Patents, P.O.
patent term extension (characterized as
Box 1450, Alexandria, VA 22313–1450,
‘‘patent term adjustment’’ in the AIPA).
marked to the attention of Kery A. Fries, Original utility and plant patents
Senior Legal Advisor, Office of Patent
issuing from applications filed on or
Legal Administration, Office of the
after May 29, 2000, may be eligible for
Associate Commissioner for Patent
patent term adjustment if issuance of
Examination Policy. Although
the patent is delayed due to one or more
comments may be submitted by mail,
of the enumerated administrative delays
the Office prefers to receive comments
listed in 35 U.S.C. 154(b)(1).
via the Internet.
Specifically, under the patent term
Comments may also be sent by
adjustment provisions of 35 U.S.C.
electronic mail message over the
154(b) as amended by the AIPA, an
Internet via the Federal eRulemaking
applicant is entitled to patent term
Portal. See the Federal eRulemaking
adjustment for the following reasons: (1)
Portal Web site (https://
If the Office fails to take certain actions
www.regulations.gov) for additional
during the examination and issue
instructions on providing comments via process within specified time frames (35
the Federal eRulemaking Portal.
U.S.C. 154(b)(1)(A)); (2) if the Office
The comments will be available for
fails to issue a patent within three years
public inspection at the Office of the
of the actual filing date of the
Commissioner for Patents, located in
application (35 U.S.C. 154(b)(1)(B)); and
Madison East, Tenth Floor, 600 Dulany
(3) for delays due to interference,
Street, Alexandria, Virginia, and will be secrecy order, or successful appellate
available via the Internet (https://
review (35 U.S.C. 154(b)(1)(C)). See 35
www.uspto.gov). Because comments will U.S.C. 154(b)(1). The AIPA, however,
be made available for public inspection, sets forth a number of conditions and
information that the submitter does not
limitations on any patent term
desire to make public, such as an
adjustment accrued under 35 U.S.C.
address or phone number, should not be 154(b)(1). Specifically, 35 U.S.C.
included in the comments.
154(b)(2)(C) provides, in part, that ‘‘[t]he
FOR FURTHER INFORMATION CONTACT: Kery period of adjustment of the term of a
A. Fries, Senior Legal Advisor, Office of patent under [35 U.S.C. 154(b)(1)] shall
be reduced by a period equal to the
Patent Legal Administration, by
period of time during which the
telephone at 571–272–7757, by mail
applicant failed to engage in reasonable
addressed to: Box Comments—Patents,
efforts to conclude prosecution of the
Commissioner for Patents, P.O. Box
application’’ and that ‘‘[t]he Director
1450, Alexandria, VA 22313–1450,
marked to the attention of Kery A. Fries. shall prescribe regulations establishing
VerDate Mar<15>2010
15:34 Apr 05, 2011
Jkt 223001
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00038
Fmt 4702
Sfmt 4702
18991
the circumstances that constitute a
failure of an applicant to engage in
reasonable efforts to conclude
processing or examination of an
application.’’ 35 U.S.C. 154(b)(2)(C)(i)
and (iii). The Office implemented the
patent term adjustment provisions of 35
U.S.C. 154(b) as amended by the AIPA,
including setting forth the
circumstances that constitute a failure of
an applicant to engage in reasonable
efforts to conclude processing or
examination of an application, in a final
rule published in September of 2000.
See Changes to Implement Patent Term
Adjustment Under Twenty-Year Patent
Term, 65 FR 56365 (Sept. 18, 2000)
(patent term adjustment final rule).
The patent term adjustment
provisions of the AIPA apply to original
(i.e., non-reissue) utility and plant
applications filed on or after May 29,
2000. See Changes to Implement Patent
Term Adjustment Under Twenty-Year
Patent Term, 65 FR at 56367. The patent
term extension provisions of the URAA
(for delays due to secrecy order,
interference or successful appellate
review) continue to apply to original
utility and plant applications filed on or
after June 8, 1995, and before May 29,
2000. See id.
Revision of Patent Term Extension
and Patent Term Adjustment Provisions
Relating to Decisions During Appellate
Review: Under the patent term
adjustment final rule published in 2000,
the Office initially stated that for a
decision by the BPAI to be ‘‘a decision
in the review reversing an adverse
determination of patentability’’ within
the meaning of 35 U.S.C
154(b)(1)(C)(iii), the decision must
sustain or reverse the rejection(s) of
claims(s) on appeal. See Changes to
Implement Patent Term Adjustment
Under Twenty-Year Patent Term, 65 FR
at 56368. The Office further stated that
a remand or other administrative order
by the BPAI even if by a merits panel
would not be considered ‘‘a decision in
the review reversing an adverse
determination of patentability’’ in the 35
U.S.C. 154(b)(1)(C)(iii). See id. at 56369.
The Office subsequently determined
that there were a number of BPAI panel
remands that conveyed the weakness in
the examiner’s adverse patentability
determination in a manner tantamount
to a decision reversing the adverse
patentability determination. See
Revision of Patent Term Adjustment
and Extensions, 69 FR 21704 (April 22,
2004) (2004 patent term adjustment/
extension final rule). Generally, the
remands resulted in the examiner
allowing the application (either with or
without further action by applicant)
without returning the application to the
E:\FR\FM\06APP1.SGM
06APP1
erowe on DSK5CLS3C1PROD with PROPOSALS-1
18992
Federal Register / Vol. 76, No. 66 / Wednesday, April 6, 2011 / Proposed Rules
BPAI for a decision on the appeal. The
2004 patent term adjustment/extension
final rule addressed the situation in
which an examiner responds to a
remand by a BPAI panel by allowing the
application (either with or without
further action by applicant), rather than
returning the application to the BPAI for
a decision on the appeal. See id. at
21705. In that situation, the BPAI panel
remand was considered ‘‘a decision in
the review reversing an adverse
determination of patentability’’ for
patent term extension and patent term
adjustment purposes. See id.; see also
37 CFR 1.701(a)(3) and 1.702(e). This
change in the 2004 patent term
adjustment/extension final rule,
however, did not apply if, after the BPAI
panel remand, appellant filed a request
for continued examination under 35
U.S.C. 132(b) (37 CFR 1.114) that was
not first preceded by the mailing, after
such remand, of an action under 35
U.S.C. 132 or a notice of allowance
under 35 U.S.C. 151. See id.; see also 37
CFR 1.701(a)(3) and 1.702(e).
In 2005, the Office instituted a pilot
program to provide an appellant the
opportunity to request that a panel of
examiners formally review the legal and
factual bases of the rejections in his or
her application prior to the filing of an
appeal brief. See New Pre-Appeal Brief
Conference Pilot Program, 1260 Off.
Gaz. Pat. Office 67 (July 12, 2005). In the
pilot program, the Office indicated that
a decision by a pre-appeal brief
conference panel to withdraw any or all
of the claims on appeal is not a decision
by the panel of the BPAI, and as such,
would not result in any patent term
adjustment or extension under 35 U.S.C.
154(b). See id.
This pilot program has resulted in a
number of situations in which
prosecution is reopened. The Office has
now concluded that it may and, in most
situations, should treat a decision in a
pre-appeal brief review reopening
prosecution and issuing an Office action
or notice of allowance as a ‘‘decision in
the review reversing an adverse
determination of patentability’’ under 35
U.S.C. 154(b)(1)(C)(iii). Prior to 2005,
the vast majority of applications in
which a notice of appeal and appeal
brief were filed were forwarded to the
BPAI for a decision on the appeal. That
is, prior to 2005, the only notable
‘‘decision in the review’’ of an
application on appeal was a decision by
the BPAI. Under current Office practice,
however, the application in which a
notice of appeal has been filed may be
subject to a pre-appeal brief review and
will be subject to a post-appeal brief
review before the application will be
forwarded to the BPAI for a decision by
VerDate Mar<15>2010
15:34 Apr 05, 2011
Jkt 223001
the BPAI. Thus, under current Office
practice, the process for seeking
appellate review by the BPAI involves at
least one decision in the review before
the application is forwarded to the
BPAI, and a decision in these pre-BPAI
reviews may result in the reopening of
prosecution and issuance of an Office
action or notice of allowance. Since in
many such situations the reopening of
the application after notice of appeal
has been filed is the result of a decision
in the pre-BPAI review that there is
some weakness in the adverse
patentability determination from which
the appeal was taken, the Office now
considers it appropriate to treat such
situations as a ‘‘decision in the review
reversing an adverse determination of
patentability’’ under 35 U.S.C.
154(b)(1)(C)(iii). Consequently, the
Office has determined that it is prudent
as a matter of policy to allow for a
correspondent positive patent term
adjustment when an examiner reverses
his or her prior rejection under these
circumstances.
Accordingly, the Office is proposing
to revise the patent term adjustment and
extension provisions to provide, with
certain exceptions, that an examiner
reopening prosecution will be
considered a ‘‘decision in the review
reversing an adverse determination of
patentability,’’ and therefore result in
the possibility of patent term adjustment
under 35 U.S.C. 154(b). The Office notes
that not all reopening of prosecution
after the filing of a notice of appeal will
be considered a ‘‘decision in the review
reversing an adverse determination of
patentability.’’ For example, the
reopening of prosecution after a notice
of appeal resulting from an applicant
filing a request for continued
examination (RCE) (proper or improper)
will not be considered a ‘‘decision in the
review reversing an adverse
determination of patentability’’ and will
not result in patent term adjustment
under 35 U.S.C. 154(b). Furthermore,
any reopening of prosecution or
issuance of a notice of allowance under
35 U.S.C. 151 resulting from an
applicant filing an amendment pursuant
to 37 CFR 41.33 canceling all claims on
appeal will not be considered a
‘‘decision in the review reversing an
adverse determination of patentability’’
and will not result in patent term
adjustment under 35 U.S.C. 154(b).
Moreover, any reopening of prosecution
or issuance of a notice of allowance
under 35 U.S.C. 151 resulting from the
applicant filing a request to dismiss or
withdraw the appeal will not be
considered a ‘‘decision in the review
reversing an adverse determination of
PO 00000
Frm 00039
Fmt 4702
Sfmt 4702
patentability’’ and will not result in
patent term adjustment under 35 U.S.C.
154(b).
If the patent issues after an examiner
reopens prosecution after the filing of a
notice of appeal, and the reopening of
prosecution is considered ‘‘a decision in
the review reversing an adverse
determination of patentability,’’ then the
reopening of prosecution is deemed by
the Office to be the ‘‘final decision in
favor of the applicant’’ for purposes of
a patent term extension or adjustment
calculation under 37 CFR 1.701(c)(3) or
1.703(e) (as applicable). The period of
extension or adjustment calculated
under 37 CFR 1.701(c)(3) or 1.703(e) (as
applicable) would equal the number of
days in the period beginning on the date
on which a notice of appeal to the BPAI
was filed under 35 U.S.C. 134 and 37
CFR 41.31 and ending on the date of
mailing of the Office action under 35
U.S.C.132 or a notice of allowance
under 35 U.S.C. 151.
Revisions of Patent Term Extension
and Patent Term Adjustment Provisions
Relating to Information Disclosure
Statements: Section 1.704(c) provides
that the submission of an information
disclosure statement either that is after
a notice of allowance or that requires a
supplemental Office action results in a
reduction of any patent term adjustment
under 37 CFR 1.703. See 37 CFR
1.704(c)(6), 1.704(c)(8), 1.704(c)(9), and
(c)(10). Section 1.704(d) provides that
an information disclosure statement will
not result in a patent term adjustment
reduction under 37 CFR 1.704(c)(6),
1.704(c)(8), 1.704(c)(9), or (c)(10) if it is
accompanied by a certification
(statement) that each item of
information contained in the
information disclosure statement was
first cited in a communication from a
foreign patent office in a counterpart
application and that this
communication was not received by any
individual designated in 37 CFR 1.56(c)
more than thirty days prior to the filing
of the information disclosure statement.
37 CFR 1.704(d) permits applicants to
submit information first cited in a
communication from a foreign patent
office in a counterpart application to the
Office without a reduction in patent
term adjustment if an information
disclosure statement is promptly
(within thirty days of receipt of the
communication) submitted to the Office.
Recent decisions by the U.S. Court of
Appeals for the Federal Circuit (Federal
Circuit) underscore the importance of
making information cited and Office
actions issued in related copending
foreign and domestic applications of
record. See Dayco Products, Inc. v. Total
Containment, Inc., 329 F.3d 1358 (Fed.
E:\FR\FM\06APP1.SGM
06APP1
Federal Register / Vol. 76, No. 66 / Wednesday, April 6, 2011 / Proposed Rules
erowe on DSK5CLS3C1PROD with PROPOSALS-1
Cir. 2003) and McKesson Info. Solutions,
Inc. v. Bridge Medical, Inc., 487 F.3d
897 (Fed. Cir. 2007); see also Larson
Mfg. Co. v. Aluminart Products Ltd., 559
F.3d 1317 (Fed. Cir. 2009) (relating to
disclosure in a U.S. reexamination
proceeding of U.S. Office actions that
were issued in a continuation
application of the patent under
reexamination). The Office is proposing
to revise 37 CFR 1.704(d) to also
embrace information first cited in a
communication from the Office, as well
as the communication (e.g., Office
action) in a counterpart foreign or
international application or from the
Office itself.
Obviously, meeting the conditions set
forth in 37 CFR 1.704(d) does not
substitute for compliance with any
relevant requirement of 37 CFR 1.97 or
1.98.
Discussion of Specific Rules
Title 37 of the Code of Federal
Regulations, Part 1, is proposed to be
amended as follows:
Section 1.701: Section 1.701(a)(3) is
proposed to be amended to take into
account the situation in which the
Office reopens prosecution after a
timely notice of appeal has been filed
but before any decision by the BPAI and
issues an Office action under 35 U.S.C.
132 (i.e., a new non-final or final Office
action) or notice of allowance under 35
U.S.C. 151. The reopening of
prosecution in this situation will in
most circumstances also be considered
a decision in the review reversing an
adverse determination of patentability
as that phrase is used in 35 U.S.C.
154(b)(2) as amended by the URAA, and
a final decision in favor of the applicant
under § 1.701(c)(3). An examiner’s
answer containing a new ground of
rejection is not an Office action under
35 U.S.C. 132, and is not the Office
reopening prosecution. Section
1.701(a)(3) is also proposed to be
amended by adding a sentence to
provide that a reopening of prosecution
after a notice of appeal has been filed
will not be considered a decision in the
review reversing an adverse
determination of patentability as
provided in § 1.701(a)(3) if appellant
files a request to withdraw the appeal,
an amendment pursuant to § 41.33
canceling all of the claims on appeal, or
a request for continued examination
under 35 U.S.C. 132(b).
Section 1.702: Section 1.702(e) is
proposed to be amended to take into
account the situation in which the
Office reopens prosecution after a
timely notice of appeal has been filed
but before any decision by the BPAI and
issues an Office action under 35 U.S.C.
VerDate Mar<15>2010
15:34 Apr 05, 2011
Jkt 223001
132 (i.e., a new non-final or final Office
action) or notice of allowance under 35
U.S.C. 151. The reopening of
prosecution in this situation will in
most circumstances also be considered
a decision by the BPAI as that phrase is
used in 35 U.S.C. 154(b)(1)(A)(iii), a
decision in the review reversing an
adverse determination of patentability
as that phrase is used in 35 U.S.C.
154(b)(1)(C)(iii), and a final decision in
favor of the applicant under § 1.703(e).
An examiner’s answer containing a new
ground of rejection is not an Office
action under 35 U.S.C. 132, and is not
the Office reopening prosecution.
Section 1.702(e) is further amended by
adding a sentence to provide that a
reopening of prosecution after a notice
of appeal has been filed will not be
considered a decision in the review
reversing an adverse determination of
patentability as provided in § 1.702(e) if
appellant files a request to withdraw the
appeal, an amendment pursuant to
§ 41.33 canceling all of the claims on
appeal, or a request for continued
examination under 35 U.S.C. 132(b).
Section 1.704: Section 1.704(d) is
amended to change ‘‘any
communication from a foreign patent
office in a counterpart application’’ to
‘‘any communication from a patent
office in a counterpart foreign or
international application or from the
Office’’ and add ‘‘ or is a communication
that was issued by a patent office in a
counterpart foreign or international
application or by the Office.’’ This
change revises § 1.704(d) to also
embrace information first cited in a
communication from the Office, as well
as the communication (e.g., Office
action) in a counterpart foreign or
international application or from the
Office itself. For example, under the
proposed rule, there would not be a
reduction of patent term adjustment in
the following situations: (1) When
applicant promptly submits a reference
in an information disclosure statement
after the mailing of a notice of
allowance if the reference was cited by
the Office in another application, or (2)
when applicant promptly submits a
copy of an Office communication (e.g.,
an Office action) in an information
disclosure statement after the mailing of
a notice of allowance if the Office
communication was issued by the Office
in another application or by a foreign
patent office in a counterpart foreign
application.
Rulemaking Considerations
A. Regulatory Flexibility Act: For the
reasons set forth herein, the Deputy
General Counsel for General Law of the
United States Patent and Trademark
PO 00000
Frm 00040
Fmt 4702
Sfmt 4702
18993
Office has certified to the Chief Counsel
for Advocacy of the Small Business
Administration that changes proposed
in this proposed rule will not have a
significant economic impact on a
substantial number of small entities. See
5 U.S.C. 605(b).
This rule making involves: (1)
Indicating that in most circumstances an
examiner reopening prosecution of the
application after a notice of appeal has
been filed will be considered a ‘‘decision
in the review reversing an adverse
determination of patentability’’ for
patent term adjustment or extension
purposes; and (2) indicating that the
exception to the patent term adjustment
reduction for filing an information
disclosure statement after a notice of
allowance or that requires a
supplemental Office action for
information disclosure statements for
information cited by a foreign patent
office in a counterpart application that
are promptly filed with the Office is
expanded to also embrace information
first cited by the Office in another
application. This proposed rule does not
propose to add any additional
requirements (including information
collection requirements) or fees for
patent applicants or patentees.
Therefore, the changes proposed in this
proposed rule will not have a significant
economic impact on a substantial
number of small entities.
B. Executive Order 12866 (Regulatory
Planning and Review): This rule making
has been determined to be not
significant for purposes of Executive
Order 12866 (Sept. 30, 1993).
C. Executive Order 13563 (Improving
Regulation and Regulatory Review): The
Office has complied with Executive
Order 13563. Specifically, the Office
has: (1) Used the best available
techniques to quantify costs and
benefits, and has considered values
such as equity, fairness and distributive
impacts; (2) provided the public with a
meaningful opportunity to participate in
the regulatory process, including
soliciting the views of those likely
affected prior to issuing a notice of
proposed rule making, and provided online access to the rule making docket;
(3) attempted to promote coordination,
simplification and harmonization across
government agencies and identified
goals designed to promote innovation;
(4) considered approaches that reduce
burdens and maintain flexibility and
freedom of choice for the public; and (5)
ensured the objectivity of scientific and
technological information and
processes, to the extent applicable.
D. Executive Order 13132
(Federalism): This rule making does not
contain policies with federalism
E:\FR\FM\06APP1.SGM
06APP1
erowe on DSK5CLS3C1PROD with PROPOSALS-1
18994
Federal Register / Vol. 76, No. 66 / Wednesday, April 6, 2011 / Proposed Rules
implications sufficient to warrant
preparation of a Federalism Assessment
under Executive Order 13132 (Aug. 4,
1999).
E. Executive Order 13175 (Tribal
Consultation): This rule making will
not: (1) Have substantial direct effects
on one or more Indian tribes; (2) impose
substantial direct compliance costs on
Indian tribal governments; or (3)
preempt tribal law. Therefore, a tribal
summary impact statement is not
required under Executive Order 13175
(Nov. 6, 2000).
F. Executive Order 13211 (Energy
Effects): This rule making is not a
significant energy action under
Executive Order 13211 because this rule
making is not likely to have a significant
adverse effect on the supply,
distribution, or use of energy. Therefore,
a Statement of Energy Effects is not
required under Executive Order 13211
(May 18, 2001).
G. Executive Order 12988 (Civil
Justice Reform): This rulemaking meets
applicable standards to minimize
litigation, eliminate ambiguity, and
reduce burden as set forth in sections
3(a) and 3(b)(2) of Executive Order
12988 (Feb. 5, 1996).
H. Executive Order 13045 (Protection
of Children): This rulemaking does not
concern an environmental risk to health
or safety that may disproportionately
affect children under Executive Order
13045 (Apr. 21, 1997).
I. Executive Order 12630 (Taking of
Private Property): This rulemaking will
not effect a taking of private property or
otherwise have taking implications
under Executive Order 12630 (Mar. 15,
1988).
J. Congressional Review Act: Under
the Congressional Review Act
provisions of the Small Business
Regulatory Enforcement Fairness Act of
1996 (5 U.S.C. 801 et seq.), prior to
issuing any final rule, the United States
Patent and Trademark Office will
submit a report containing the final rule
and other required information to the
U.S. Senate, the U.S. House of
Representatives and the Comptroller
General of the Government
Accountability Office. The changes in
this proposed rule are not expected to
result in an annual effect on the
economy of 100 million dollars or more,
a major increase in costs or prices, or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or the ability
of United States-based enterprises to
compete with foreign-based enterprises
in domestic and export markets.
Therefore, this proposed rule is not
expected to result in a ‘‘major rule’’ as
defined in 5 U.S.C. 804(2).
VerDate Mar<15>2010
15:34 Apr 05, 2011
Jkt 223001
K. Unfunded Mandates Reform Act of
1995: The changes proposed in this
proposed rule do not involve a Federal
intergovernmental mandate that will
result in the expenditure by State, local,
and tribal governments, in the aggregate,
of 100 million dollars (as adjusted) or
more in any one year, or a Federal
private sector mandate that will result
in the expenditure by the private sector
of 100 million dollars (as adjusted) or
more in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions are
necessary under the provisions of the
Unfunded Mandates Reform Act of
1995. See 2 U.S.C. 1501 et seq.
L. National Environmental Policy Act:
This rulemaking will not have any effect
on the quality of environment and is
thus categorically excluded from review
under the National Environmental
Policy Act of 1969. See 42 U.S.C. 4321
et seq.
M. National Technology Transfer and
Advancement Act: The requirements of
section 12(d) of the National
Technology Transfer and Advancement
Act of 1995 (15 U.S.C. 272 note) are not
applicable because this rulemaking does
not contain provisions which involve
the use of technical standards.
N. Paperwork Reduction Act: The
rules of practice pertaining to patent
term adjustment and extension have
been reviewed and approved by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.)
under OMB control number 0651–0020.
As discussed previously, this
rulemaking involves: (1) Indicating that
in most circumstances an examiner
reopening prosecution of the
application after a notice of appeal has
been filed will be considered a ‘‘decision
in the review reversing an adverse
determination of patentability’’ for
patent term adjustment or extension
purposes; and (2) indicating that the
exception to the patent term adjustment
reduction for filing an information
disclosure statement after a notice of
allowance or that requires a
supplemental Office action for
information disclosure statements for
information cited by a foreign patent
office in a counterpart application that
are promptly filed with the Office is
expanded to also embrace information
first cited by the Office in another
application. This proposed rule does not
propose to add any additional
requirements (including information
collection requirements) or fees for
patent applicants or patentees.
Therefore, the Office is not resubmitting
information collection packages to OMB
for its review and approval because the
PO 00000
Frm 00041
Fmt 4702
Sfmt 4702
changes proposed in this proposed rule
do not affect the information collection
requirements associated with the
information collections under OMB
control number 0651–0020.
Notwithstanding any other provision
of law, no person is required to respond
to nor shall any person be subject to a
penalty for failure to comply with a
collection of information subject to the
requirements of the Paperwork
Reduction Act unless that collection of
information displays a currently valid
OMB control number.
List of Subjects in 37 CFR Part 1
Administrative practice and
procedure, Courts, Freedom of
Information, Inventions and patents,
Reporting and record keeping
requirements, Small Businesses.
For the reasons set forth in the
preamble, 37 CFR part 1 is proposed to
be amended as follows:
PART 1—RULES OF PRACTICE IN
PATENT CASES
1. The authority citation for 37 CFR
part 1 continues to read as follows:
Authority: 35 U.S.C. 2(b)(2).
2. Section 1.701 is amended by
revising paragraph (a)(3) to read as
follows:
§ 1.701 Extension of patent term due to
examination delay under the Uruguay
Round Agreements Act (original
applications, other than designs, filed on or
after June 8, 1995, and before May 29,
2000).
(a) * * *
(3) Appellate review by the Board of
Patent Appeals and Interferences or by
a Federal court under 35 U.S.C. 141 or
145, if the patent was issued pursuant
to a decision in the review reversing an
adverse determination of patentability
and if the patent is not subject to a
terminal disclaimer due to the issuance
of another patent claiming subject
matter that is not patentably distinct
from that under appellate review. If an
application is remanded by a panel of
the Board of Patent Appeals and
Interferences and the remand is the last
action by a panel of the Board of Patent
Appeals and Interferences prior to the
mailing of a notice of allowance under
35 U.S.C. 151 in the application or if the
Office reopens prosecution after a notice
of appeal has been filed but before any
decision by the Board of Patent Appeals
and Interferences and issues an Office
action under 35 U.S.C. 132 or notice of
allowance under 35 U.S.C. 151, the
remand or issuance of an Office action
under 35 U.S.C. 132 or notice of
allowance under 35 U.S.C. 151 shall be
E:\FR\FM\06APP1.SGM
06APP1
Federal Register / Vol. 76, No. 66 / Wednesday, April 6, 2011 / Proposed Rules
considered a decision in the review
reversing an adverse determination of
patentability as that phrase is used in 35
U.S.C. 154(b)(2) as amended by section
532(a) of the Uruguay Round
Agreements Act, Public Law 103–465,
108 Stat. 4809, 4983–85 (1994), and a
final decision in favor of the applicant
under paragraph (c)(3) of this section. A
remand by a panel of the Board of
Patent Appeals and Interferences shall
not be considered a decision in the
review reversing an adverse
determination of patentability as
provided in this paragraph if there is
filed a request for continued
examination under 35 U.S.C. 132(b) that
was not first preceded by the mailing,
after such remand, of at least one of an
action under 35 U.S.C. 132 or a notice
of allowance under 35 U.S.C. 151. A
reopening of prosecution after a notice
of appeal has been filed shall not be
considered a decision in the review
reversing an adverse determination as
provided in this paragraph if appellant
files a request to withdraw the appeal,
an amendment pursuant to § 41.33 of
this chapter canceling all of the claims
on appeal, or a request for continued
examination under 35 U.S.C. 132(b).
*
*
*
*
*
3. Section 1.702 is proposed to be
amended by revising paragraph (e) to
read as follows:
§ 1.702 Grounds for adjustment of patent
term due to examination delay under the
Patent Term Guarantee Act of 1999 (original
applications, other than designs, filed on or
after May 29, 2000).
erowe on DSK5CLS3C1PROD with PROPOSALS-1
*
*
*
*
*
(e) Delays caused by successful
appellate review. Subject to the
provisions of 35 U.S.C. 154(b) and this
subpart, the term of an original patent
shall be adjusted if the issuance of the
patent was delayed due to review by the
Board of Patent Appeals and
Interferences under 35 U.S.C. 134 or by
a Federal court under 35 U.S.C. 141 or
145, if the patent was issued under a
decision in the review reversing an
adverse determination of patentability.
If an application is remanded by a panel
of the Board of Patent Appeals and
Interferences and the remand is the last
action by a panel of the Board of Patent
Appeals and Interferences prior to the
mailing of a notice of allowance under
35 U.S.C. 151 in the application or if the
Office reopens prosecution after a notice
of appeal has been filed but before any
decision by the Board of Patent Appeals
and Interferences and issues an Office
action under 35 U.S.C. 132 or notice of
allowance under 35 U.S.C. 151, the
remand or issuance of an Office action
under 35 U.S.C. 132 or notice of
VerDate Mar<15>2010
15:34 Apr 05, 2011
Jkt 223001
allowance under 35 U.S.C. 151 shall be
considered a decision in the review
reversing an adverse determination of
patentability as that phrase is used in 35
U.S.C. 154(b)(1)(C)(iii), and a final
decision in favor of the applicant under
§ 1.703(e). A remand by a panel of the
Board of Patent Appeals and
Interferences shall not be considered a
decision in the review reversing an
adverse determination of patentability
as provided in this paragraph if there is
filed a request for continued
examination under 35 U.S.C. 132(b) that
was not first preceded by the mailing,
after such remand, of at least one of an
action under 35 U.S.C. 132 or a notice
of allowance under 35 U.S.C. 151. A
reopening of prosecution after a notice
of appeal has been filed shall not be
considered a decision in the review
reversing an adverse determination as
provided in this paragraph if appellant
files a request to withdraw the appeal,
an amendment pursuant to § 41.33 of
this title canceling all of the claims on
appeal, or a request for continued
examination under 35 U.S.C. 132(b).
*
*
*
*
*
4. Section 1.704 is amended by
revising paragraph (d) to read as
follows:
§ 1.704 Reduction of period of adjustment
of patent term.
*
*
*
*
*
(d)(1) A paper containing only an
information disclosure statement in
compliance with §§ 1.97 and 1.98 will
not be considered a failure to engage in
reasonable efforts to conclude
prosecution (processing or examination)
of the application under paragraphs
(c)(6), (c)(8), (c)(9), or (c)(10) of this
section if it is accompanied by a
statement that each item of information
contained in the information disclosure
statement:
(i) Was first cited in any
communication from a patent office in
a counterpart foreign or international
application or from the Office and this
communication was not received by any
individual designated in § 1.56(c) more
than thirty days prior to the filing of the
information disclosure statement; or
(ii) Is a communication that was
issued by a patent office in a
counterpart foreign or international
application or by the Office and this
communication was not received by any
individual designated in § 1.56(c) more
than thirty days prior to the filing of the
information disclosure statement.
PO 00000
Frm 00042
Fmt 4702
Sfmt 4702
18995
(2) The thirty-day period set forth in
paragraph (d)(1) of this section is not
extendable.
*
*
*
*
*
Teresa Stanek Rea,
Deputy Under Secretary of Commerce for
Intellectual Property and Deputy Director of
the United States Patent and Trademark
Office.
[FR Doc. 2011–8275 Filed 4–5–11; 8:45 am]
BILLING CODE 3510–16–P
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 168
[EPA–HQ–OPP–2009–0607; FRL–8862–2]
RIN 2070–AJ53
Pesticides; Regulation to Clarify
Labeling of Pesticides for Export
Environmental Protection
Agency (EPA).
ACTION: Proposed rule.
AGENCY:
EPA is proposing to revise the
regulations on labeling of pesticides and
devices intended for export. Internal
review of the regulations revealed that
the current regulations needed
clarification and restructuring to
increase understandability and ease of
use.
SUMMARY:
Comments must be received on
or before June 6, 2011.
ADDRESSES: Submit your comments,
identified by docket identification (ID)
number EPA–HQ—OPP–2009–0607, by
one of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the on-line
instructions for submitting comments.
• Mail: Office of Pesticide Programs
(OPP) Regulatory Public Docket (7502P),
Environmental Protection Agency, 1200
Pennsylvania Ave., NW., Washington,
DC 20460–0001.
• Delivery: OPP Regulatory Public
Docket (7502P), Environmental
Protection Agency, Rm. S–4400, One
Potomac Yard (South Bldg.), 2777 S.
Crystal Dr., Arlington, VA. Deliveries
are only accepted during the Docket
Facility’s normal hours of operation
(8:30 a.m. to 4 p.m., Monday through
Friday, excluding legal holidays).
Special arrangements should be made
for deliveries of boxed information, The
Docket Facility telephone number is
(703) 305–5805.
Instructions: Direct your comments to
docket ID number EPA–HQ–OPP–2009–
0607. EPA’s policy is that all comments
received will be included in the docket
without change and may be made
DATES:
E:\FR\FM\06APP1.SGM
06APP1
Agencies
[Federal Register Volume 76, Number 66 (Wednesday, April 6, 2011)]
[Proposed Rules]
[Pages 18990-18995]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-8275]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
37 CFR Part 1
[Docket No.: PTO-P-2011-0014]
RIN 0651-AC56
Revision of Patent Term Extension and Adjustment Provisions
Relating to Appellate Review and Information Disclosure Statements
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of proposed rulemaking.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office (Office) is
proposing to revise the patent term adjustment and extension provisions
of the rules of practice in patent cases. The patent term adjustment
provisions of the American Inventors Protection Act of 1999 (AIPA) and
the patent term extension provisions of the Uruguay Round Agreements
Act (URAA) each provide for patent term extension or adjustment if the
issuance of the patent was delayed due to appellate review by the Board
of Patent Appeals and Interferences (BPAI) or by a Federal court and
the patent was issued pursuant to or under a decision in the review
reversing an adverse determination of patentability. The Office is
proposing to change the rules of practice to indicate that in most
circumstances an examiner reopening prosecution of the application
after a notice of appeal has been filed will be considered a decision
in the review reversing an adverse determination of patentability for
purposes of patent term adjustment or extension purposes. Therefore, in
such situations, patentees would be entitled to patent term extension
or adjustment. In addition, the AIPA provides for a reduction of any
patent term adjustment if the applicant failed to engage in reasonable
efforts to conclude prosecution of the application. The Office is also
proposing to change the rules of practice pertaining to the reduction
of patent term adjustment for applicant delays to exclude information
disclosure statements resulting from the citation of information by a
foreign patent office in a counterpart
[[Page 18991]]
application that are promptly filed with the Office. For example, under
the proposed rule, there would not be a reduction of patent term
adjustment in the following situations: When applicant promptly submits
a reference in an information disclosure statement after the mailing of
a notice of allowance if the reference was cited by the Office in
another application, or when applicant promptly submits a copy of an
Office communication (e.g., an Office action) in an information
disclosure statement after the mailing of a notice of allowance if the
Office communication was issued by the Office in another application or
by a foreign patent office in a counterpart foreign application.
DATES: Written comments must be received on or before May 6, 2011. No
public hearing will be held.
ADDRESSES: Comments concerning this proposed rule should be sent by
electronic mail message over the Internet addressed to
AC56.comments@uspto.gov. Comments may also be submitted by mail
addressed to: Mail Stop Comments--Patents, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450, marked to the attention of
Kery A. Fries, Senior Legal Advisor, Office of Patent Legal
Administration, Office of the Associate Commissioner for Patent
Examination Policy. Although comments may be submitted by mail, the
Office prefers to receive comments via the Internet.
Comments may also be sent by electronic mail message over the
Internet via the Federal eRulemaking Portal. See the Federal
eRulemaking Portal Web site (https://www.regulations.gov) for additional
instructions on providing comments via the Federal eRulemaking Portal.
The comments will be available for public inspection at the Office
of the Commissioner for Patents, located in Madison East, Tenth Floor,
600 Dulany Street, Alexandria, Virginia, and will be available via the
Internet (https://www.uspto.gov). Because comments will be made
available for public inspection, information that the submitter does
not desire to make public, such as an address or phone number, should
not be included in the comments.
FOR FURTHER INFORMATION CONTACT: Kery A. Fries, Senior Legal Advisor,
Office of Patent Legal Administration, by telephone at 571-272-7757, by
mail addressed to: Box Comments--Patents, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450, marked to the attention of
Kery A. Fries.
SUPPLEMENTARY INFORMATION: Section 532(a) of the URAA (Pub. L. 103-465,
108 Stat. 4809 (1994)) amended 35 U.S.C. 154 to provide that the term
of a patent ends on the date that is twenty years from the filing date
of the application, or the earliest filing date for which a benefit is
claimed under 35 U.S.C. 120, 121, or 365(c). The URAA also contained
provisions, codified at 35 U.S.C. 154(b), for patent term extension due
to certain examination delays. Under the patent term extension
provisions of 35 U.S.C. 154(b) as amended by the URAA, an applicant is
entitled to patent term extension for delays due to interference,
secrecy order, or successful appellate review. See 35 U.S.C. 154(b)
(1995). The Office implemented the patent term extension provisions of
the URAA in a final rule published in April of 1995. See Changes to
Implement 20-Year Patent Term and Provisional Applications, 60 FR 20195
(Apr. 25, 1995) (twenty-year patent term final rule).
The AIPA (Pub. L. 106-113, 113 Stat. 1501, 1501A-552 through 1501A-
591 (1999)) further amended 35 U.S.C. 154(b) to include additional
bases for patent term extension (characterized as ``patent term
adjustment'' in the AIPA). Original utility and plant patents issuing
from applications filed on or after May 29, 2000, may be eligible for
patent term adjustment if issuance of the patent is delayed due to one
or more of the enumerated administrative delays listed in 35 U.S.C.
154(b)(1). Specifically, under the patent term adjustment provisions of
35 U.S.C. 154(b) as amended by the AIPA, an applicant is entitled to
patent term adjustment for the following reasons: (1) If the Office
fails to take certain actions during the examination and issue process
within specified time frames (35 U.S.C. 154(b)(1)(A)); (2) if the
Office fails to issue a patent within three years of the actual filing
date of the application (35 U.S.C. 154(b)(1)(B)); and (3) for delays
due to interference, secrecy order, or successful appellate review (35
U.S.C. 154(b)(1)(C)). See 35 U.S.C. 154(b)(1). The AIPA, however, sets
forth a number of conditions and limitations on any patent term
adjustment accrued under 35 U.S.C. 154(b)(1). Specifically, 35 U.S.C.
154(b)(2)(C) provides, in part, that ``[t]he period of adjustment of
the term of a patent under [35 U.S.C. 154(b)(1)] shall be reduced by a
period equal to the period of time during which the applicant failed to
engage in reasonable efforts to conclude prosecution of the
application'' and that ``[t]he Director shall prescribe regulations
establishing the circumstances that constitute a failure of an
applicant to engage in reasonable efforts to conclude processing or
examination of an application.'' 35 U.S.C. 154(b)(2)(C)(i) and (iii).
The Office implemented the patent term adjustment provisions of 35
U.S.C. 154(b) as amended by the AIPA, including setting forth the
circumstances that constitute a failure of an applicant to engage in
reasonable efforts to conclude processing or examination of an
application, in a final rule published in September of 2000. See
Changes to Implement Patent Term Adjustment Under Twenty-Year Patent
Term, 65 FR 56365 (Sept. 18, 2000) (patent term adjustment final rule).
The patent term adjustment provisions of the AIPA apply to original
(i.e., non-reissue) utility and plant applications filed on or after
May 29, 2000. See Changes to Implement Patent Term Adjustment Under
Twenty-Year Patent Term, 65 FR at 56367. The patent term extension
provisions of the URAA (for delays due to secrecy order, interference
or successful appellate review) continue to apply to original utility
and plant applications filed on or after June 8, 1995, and before May
29, 2000. See id.
Revision of Patent Term Extension and Patent Term Adjustment
Provisions Relating to Decisions During Appellate Review: Under the
patent term adjustment final rule published in 2000, the Office
initially stated that for a decision by the BPAI to be ``a decision in
the review reversing an adverse determination of patentability'' within
the meaning of 35 U.S.C 154(b)(1)(C)(iii), the decision must sustain or
reverse the rejection(s) of claims(s) on appeal. See Changes to
Implement Patent Term Adjustment Under Twenty-Year Patent Term, 65 FR
at 56368. The Office further stated that a remand or other
administrative order by the BPAI even if by a merits panel would not be
considered ``a decision in the review reversing an adverse
determination of patentability'' in the 35 U.S.C. 154(b)(1)(C)(iii).
See id. at 56369.
The Office subsequently determined that there were a number of BPAI
panel remands that conveyed the weakness in the examiner's adverse
patentability determination in a manner tantamount to a decision
reversing the adverse patentability determination. See Revision of
Patent Term Adjustment and Extensions, 69 FR 21704 (April 22, 2004)
(2004 patent term adjustment/extension final rule). Generally, the
remands resulted in the examiner allowing the application (either with
or without further action by applicant) without returning the
application to the
[[Page 18992]]
BPAI for a decision on the appeal. The 2004 patent term adjustment/
extension final rule addressed the situation in which an examiner
responds to a remand by a BPAI panel by allowing the application
(either with or without further action by applicant), rather than
returning the application to the BPAI for a decision on the appeal. See
id. at 21705. In that situation, the BPAI panel remand was considered
``a decision in the review reversing an adverse determination of
patentability'' for patent term extension and patent term adjustment
purposes. See id.; see also 37 CFR 1.701(a)(3) and 1.702(e). This
change in the 2004 patent term adjustment/extension final rule,
however, did not apply if, after the BPAI panel remand, appellant filed
a request for continued examination under 35 U.S.C. 132(b) (37 CFR
1.114) that was not first preceded by the mailing, after such remand,
of an action under 35 U.S.C. 132 or a notice of allowance under 35
U.S.C. 151. See id.; see also 37 CFR 1.701(a)(3) and 1.702(e).
In 2005, the Office instituted a pilot program to provide an
appellant the opportunity to request that a panel of examiners formally
review the legal and factual bases of the rejections in his or her
application prior to the filing of an appeal brief. See New Pre-Appeal
Brief Conference Pilot Program, 1260 Off. Gaz. Pat. Office 67 (July 12,
2005). In the pilot program, the Office indicated that a decision by a
pre-appeal brief conference panel to withdraw any or all of the claims
on appeal is not a decision by the panel of the BPAI, and as such,
would not result in any patent term adjustment or extension under 35
U.S.C. 154(b). See id.
This pilot program has resulted in a number of situations in which
prosecution is reopened. The Office has now concluded that it may and,
in most situations, should treat a decision in a pre-appeal brief
review reopening prosecution and issuing an Office action or notice of
allowance as a ``decision in the review reversing an adverse
determination of patentability'' under 35 U.S.C. 154(b)(1)(C)(iii).
Prior to 2005, the vast majority of applications in which a notice of
appeal and appeal brief were filed were forwarded to the BPAI for a
decision on the appeal. That is, prior to 2005, the only notable
``decision in the review'' of an application on appeal was a decision
by the BPAI. Under current Office practice, however, the application in
which a notice of appeal has been filed may be subject to a pre-appeal
brief review and will be subject to a post-appeal brief review before
the application will be forwarded to the BPAI for a decision by the
BPAI. Thus, under current Office practice, the process for seeking
appellate review by the BPAI involves at least one decision in the
review before the application is forwarded to the BPAI, and a decision
in these pre-BPAI reviews may result in the reopening of prosecution
and issuance of an Office action or notice of allowance. Since in many
such situations the reopening of the application after notice of appeal
has been filed is the result of a decision in the pre-BPAI review that
there is some weakness in the adverse patentability determination from
which the appeal was taken, the Office now considers it appropriate to
treat such situations as a ``decision in the review reversing an
adverse determination of patentability'' under 35 U.S.C.
154(b)(1)(C)(iii). Consequently, the Office has determined that it is
prudent as a matter of policy to allow for a correspondent positive
patent term adjustment when an examiner reverses his or her prior
rejection under these circumstances.
Accordingly, the Office is proposing to revise the patent term
adjustment and extension provisions to provide, with certain
exceptions, that an examiner reopening prosecution will be considered a
``decision in the review reversing an adverse determination of
patentability,'' and therefore result in the possibility of patent term
adjustment under 35 U.S.C. 154(b). The Office notes that not all
reopening of prosecution after the filing of a notice of appeal will be
considered a ``decision in the review reversing an adverse
determination of patentability.'' For example, the reopening of
prosecution after a notice of appeal resulting from an applicant filing
a request for continued examination (RCE) (proper or improper) will not
be considered a ``decision in the review reversing an adverse
determination of patentability'' and will not result in patent term
adjustment under 35 U.S.C. 154(b). Furthermore, any reopening of
prosecution or issuance of a notice of allowance under 35 U.S.C. 151
resulting from an applicant filing an amendment pursuant to 37 CFR
41.33 canceling all claims on appeal will not be considered a
``decision in the review reversing an adverse determination of
patentability'' and will not result in patent term adjustment under 35
U.S.C. 154(b). Moreover, any reopening of prosecution or issuance of a
notice of allowance under 35 U.S.C. 151 resulting from the applicant
filing a request to dismiss or withdraw the appeal will not be
considered a ``decision in the review reversing an adverse
determination of patentability'' and will not result in patent term
adjustment under 35 U.S.C. 154(b).
If the patent issues after an examiner reopens prosecution after
the filing of a notice of appeal, and the reopening of prosecution is
considered ``a decision in the review reversing an adverse
determination of patentability,'' then the reopening of prosecution is
deemed by the Office to be the ``final decision in favor of the
applicant'' for purposes of a patent term extension or adjustment
calculation under 37 CFR 1.701(c)(3) or 1.703(e) (as applicable). The
period of extension or adjustment calculated under 37 CFR 1.701(c)(3)
or 1.703(e) (as applicable) would equal the number of days in the
period beginning on the date on which a notice of appeal to the BPAI
was filed under 35 U.S.C. 134 and 37 CFR 41.31 and ending on the date
of mailing of the Office action under 35 U.S.C.132 or a notice of
allowance under 35 U.S.C. 151.
Revisions of Patent Term Extension and Patent Term Adjustment
Provisions Relating to Information Disclosure Statements: Section
1.704(c) provides that the submission of an information disclosure
statement either that is after a notice of allowance or that requires a
supplemental Office action results in a reduction of any patent term
adjustment under 37 CFR 1.703. See 37 CFR 1.704(c)(6), 1.704(c)(8),
1.704(c)(9), and (c)(10). Section 1.704(d) provides that an information
disclosure statement will not result in a patent term adjustment
reduction under 37 CFR 1.704(c)(6), 1.704(c)(8), 1.704(c)(9), or
(c)(10) if it is accompanied by a certification (statement) that each
item of information contained in the information disclosure statement
was first cited in a communication from a foreign patent office in a
counterpart application and that this communication was not received by
any individual designated in 37 CFR 1.56(c) more than thirty days prior
to the filing of the information disclosure statement. 37 CFR 1.704(d)
permits applicants to submit information first cited in a communication
from a foreign patent office in a counterpart application to the Office
without a reduction in patent term adjustment if an information
disclosure statement is promptly (within thirty days of receipt of the
communication) submitted to the Office.
Recent decisions by the U.S. Court of Appeals for the Federal
Circuit (Federal Circuit) underscore the importance of making
information cited and Office actions issued in related copending
foreign and domestic applications of record. See Dayco Products, Inc.
v. Total Containment, Inc., 329 F.3d 1358 (Fed.
[[Page 18993]]
Cir. 2003) and McKesson Info. Solutions, Inc. v. Bridge Medical, Inc.,
487 F.3d 897 (Fed. Cir. 2007); see also Larson Mfg. Co. v. Aluminart
Products Ltd., 559 F.3d 1317 (Fed. Cir. 2009) (relating to disclosure
in a U.S. reexamination proceeding of U.S. Office actions that were
issued in a continuation application of the patent under
reexamination). The Office is proposing to revise 37 CFR 1.704(d) to
also embrace information first cited in a communication from the
Office, as well as the communication (e.g., Office action) in a
counterpart foreign or international application or from the Office
itself.
Obviously, meeting the conditions set forth in 37 CFR 1.704(d) does
not substitute for compliance with any relevant requirement of 37 CFR
1.97 or 1.98.
Discussion of Specific Rules
Title 37 of the Code of Federal Regulations, Part 1, is proposed to
be amended as follows:
Section 1.701: Section 1.701(a)(3) is proposed to be amended to
take into account the situation in which the Office reopens prosecution
after a timely notice of appeal has been filed but before any decision
by the BPAI and issues an Office action under 35 U.S.C. 132 (i.e., a
new non-final or final Office action) or notice of allowance under 35
U.S.C. 151. The reopening of prosecution in this situation will in most
circumstances also be considered a decision in the review reversing an
adverse determination of patentability as that phrase is used in 35
U.S.C. 154(b)(2) as amended by the URAA, and a final decision in favor
of the applicant under Sec. 1.701(c)(3). An examiner's answer
containing a new ground of rejection is not an Office action under 35
U.S.C. 132, and is not the Office reopening prosecution. Section
1.701(a)(3) is also proposed to be amended by adding a sentence to
provide that a reopening of prosecution after a notice of appeal has
been filed will not be considered a decision in the review reversing an
adverse determination of patentability as provided in Sec. 1.701(a)(3)
if appellant files a request to withdraw the appeal, an amendment
pursuant to Sec. 41.33 canceling all of the claims on appeal, or a
request for continued examination under 35 U.S.C. 132(b).
Section 1.702: Section 1.702(e) is proposed to be amended to take
into account the situation in which the Office reopens prosecution
after a timely notice of appeal has been filed but before any decision
by the BPAI and issues an Office action under 35 U.S.C. 132 (i.e., a
new non-final or final Office action) or notice of allowance under 35
U.S.C. 151. The reopening of prosecution in this situation will in most
circumstances also be considered a decision by the BPAI as that phrase
is used in 35 U.S.C. 154(b)(1)(A)(iii), a decision in the review
reversing an adverse determination of patentability as that phrase is
used in 35 U.S.C. 154(b)(1)(C)(iii), and a final decision in favor of
the applicant under Sec. 1.703(e). An examiner's answer containing a
new ground of rejection is not an Office action under 35 U.S.C. 132,
and is not the Office reopening prosecution. Section 1.702(e) is
further amended by adding a sentence to provide that a reopening of
prosecution after a notice of appeal has been filed will not be
considered a decision in the review reversing an adverse determination
of patentability as provided in Sec. 1.702(e) if appellant files a
request to withdraw the appeal, an amendment pursuant to Sec. 41.33
canceling all of the claims on appeal, or a request for continued
examination under 35 U.S.C. 132(b).
Section 1.704: Section 1.704(d) is amended to change ``any
communication from a foreign patent office in a counterpart
application'' to ``any communication from a patent office in a
counterpart foreign or international application or from the Office''
and add `` or is a communication that was issued by a patent office in
a counterpart foreign or international application or by the Office.''
This change revises Sec. 1.704(d) to also embrace information first
cited in a communication from the Office, as well as the communication
(e.g., Office action) in a counterpart foreign or international
application or from the Office itself. For example, under the proposed
rule, there would not be a reduction of patent term adjustment in the
following situations: (1) When applicant promptly submits a reference
in an information disclosure statement after the mailing of a notice of
allowance if the reference was cited by the Office in another
application, or (2) when applicant promptly submits a copy of an Office
communication (e.g., an Office action) in an information disclosure
statement after the mailing of a notice of allowance if the Office
communication was issued by the Office in another application or by a
foreign patent office in a counterpart foreign application.
Rulemaking Considerations
A. Regulatory Flexibility Act: For the reasons set forth herein,
the Deputy General Counsel for General Law of the United States Patent
and Trademark Office has certified to the Chief Counsel for Advocacy of
the Small Business Administration that changes proposed in this
proposed rule will not have a significant economic impact on a
substantial number of small entities. See 5 U.S.C. 605(b).
This rule making involves: (1) Indicating that in most
circumstances an examiner reopening prosecution of the application
after a notice of appeal has been filed will be considered a ``decision
in the review reversing an adverse determination of patentability'' for
patent term adjustment or extension purposes; and (2) indicating that
the exception to the patent term adjustment reduction for filing an
information disclosure statement after a notice of allowance or that
requires a supplemental Office action for information disclosure
statements for information cited by a foreign patent office in a
counterpart application that are promptly filed with the Office is
expanded to also embrace information first cited by the Office in
another application. This proposed rule does not propose to add any
additional requirements (including information collection requirements)
or fees for patent applicants or patentees. Therefore, the changes
proposed in this proposed rule will not have a significant economic
impact on a substantial number of small entities.
B. Executive Order 12866 (Regulatory Planning and Review): This
rule making has been determined to be not significant for purposes of
Executive Order 12866 (Sept. 30, 1993).
C. Executive Order 13563 (Improving Regulation and Regulatory
Review): The Office has complied with Executive Order 13563.
Specifically, the Office has: (1) Used the best available techniques to
quantify costs and benefits, and has considered values such as equity,
fairness and distributive impacts; (2) provided the public with a
meaningful opportunity to participate in the regulatory process,
including soliciting the views of those likely affected prior to
issuing a notice of proposed rule making, and provided on-line access
to the rule making docket; (3) attempted to promote coordination,
simplification and harmonization across government agencies and
identified goals designed to promote innovation; (4) considered
approaches that reduce burdens and maintain flexibility and freedom of
choice for the public; and (5) ensured the objectivity of scientific
and technological information and processes, to the extent applicable.
D. Executive Order 13132 (Federalism): This rule making does not
contain policies with federalism
[[Page 18994]]
implications sufficient to warrant preparation of a Federalism
Assessment under Executive Order 13132 (Aug. 4, 1999).
E. Executive Order 13175 (Tribal Consultation): This rule making
will not: (1) Have substantial direct effects on one or more Indian
tribes; (2) impose substantial direct compliance costs on Indian tribal
governments; or (3) preempt tribal law. Therefore, a tribal summary
impact statement is not required under Executive Order 13175 (Nov. 6,
2000).
F. Executive Order 13211 (Energy Effects): This rule making is not
a significant energy action under Executive Order 13211 because this
rule making is not likely to have a significant adverse effect on the
supply, distribution, or use of energy. Therefore, a Statement of
Energy Effects is not required under Executive Order 13211 (May 18,
2001).
G. Executive Order 12988 (Civil Justice Reform): This rulemaking
meets applicable standards to minimize litigation, eliminate ambiguity,
and reduce burden as set forth in sections 3(a) and 3(b)(2) of
Executive Order 12988 (Feb. 5, 1996).
H. Executive Order 13045 (Protection of Children): This rulemaking
does not concern an environmental risk to health or safety that may
disproportionately affect children under Executive Order 13045 (Apr.
21, 1997).
I. Executive Order 12630 (Taking of Private Property): This
rulemaking will not effect a taking of private property or otherwise
have taking implications under Executive Order 12630 (Mar. 15, 1988).
J. Congressional Review Act: Under the Congressional Review Act
provisions of the Small Business Regulatory Enforcement Fairness Act of
1996 (5 U.S.C. 801 et seq.), prior to issuing any final rule, the
United States Patent and Trademark Office will submit a report
containing the final rule and other required information to the U.S.
Senate, the U.S. House of Representatives and the Comptroller General
of the Government Accountability Office. The changes in this proposed
rule are not expected to result in an annual effect on the economy of
100 million dollars or more, a major increase in costs or prices, or
significant adverse effects on competition, employment, investment,
productivity, innovation, or the ability of United States-based
enterprises to compete with foreign-based enterprises in domestic and
export markets. Therefore, this proposed rule is not expected to result
in a ``major rule'' as defined in 5 U.S.C. 804(2).
K. Unfunded Mandates Reform Act of 1995: The changes proposed in
this proposed rule do not involve a Federal intergovernmental mandate
that will result in the expenditure by State, local, and tribal
governments, in the aggregate, of 100 million dollars (as adjusted) or
more in any one year, or a Federal private sector mandate that will
result in the expenditure by the private sector of 100 million dollars
(as adjusted) or more in any one year, and will not significantly or
uniquely affect small governments. Therefore, no actions are necessary
under the provisions of the Unfunded Mandates Reform Act of 1995. See 2
U.S.C. 1501 et seq.
L. National Environmental Policy Act: This rulemaking will not have
any effect on the quality of environment and is thus categorically
excluded from review under the National Environmental Policy Act of
1969. See 42 U.S.C. 4321 et seq.
M. National Technology Transfer and Advancement Act: The
requirements of section 12(d) of the National Technology Transfer and
Advancement Act of 1995 (15 U.S.C. 272 note) are not applicable because
this rulemaking does not contain provisions which involve the use of
technical standards.
N. Paperwork Reduction Act: The rules of practice pertaining to
patent term adjustment and extension have been reviewed and approved by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.) under OMB control number 0651-
0020. As discussed previously, this rulemaking involves: (1) Indicating
that in most circumstances an examiner reopening prosecution of the
application after a notice of appeal has been filed will be considered
a ``decision in the review reversing an adverse determination of
patentability'' for patent term adjustment or extension purposes; and
(2) indicating that the exception to the patent term adjustment
reduction for filing an information disclosure statement after a notice
of allowance or that requires a supplemental Office action for
information disclosure statements for information cited by a foreign
patent office in a counterpart application that are promptly filed with
the Office is expanded to also embrace information first cited by the
Office in another application. This proposed rule does not propose to
add any additional requirements (including information collection
requirements) or fees for patent applicants or patentees. Therefore,
the Office is not resubmitting information collection packages to OMB
for its review and approval because the changes proposed in this
proposed rule do not affect the information collection requirements
associated with the information collections under OMB control number
0651-0020.
Notwithstanding any other provision of law, no person is required
to respond to nor shall any person be subject to a penalty for failure
to comply with a collection of information subject to the requirements
of the Paperwork Reduction Act unless that collection of information
displays a currently valid OMB control number.
List of Subjects in 37 CFR Part 1
Administrative practice and procedure, Courts, Freedom of
Information, Inventions and patents, Reporting and record keeping
requirements, Small Businesses.
For the reasons set forth in the preamble, 37 CFR part 1 is
proposed to be amended as follows:
PART 1--RULES OF PRACTICE IN PATENT CASES
1. The authority citation for 37 CFR part 1 continues to read as
follows:
Authority: 35 U.S.C. 2(b)(2).
2. Section 1.701 is amended by revising paragraph (a)(3) to read as
follows:
Sec. 1.701 Extension of patent term due to examination delay under
the Uruguay Round Agreements Act (original applications, other than
designs, filed on or after June 8, 1995, and before May 29, 2000).
(a) * * *
(3) Appellate review by the Board of Patent Appeals and
Interferences or by a Federal court under 35 U.S.C. 141 or 145, if the
patent was issued pursuant to a decision in the review reversing an
adverse determination of patentability and if the patent is not subject
to a terminal disclaimer due to the issuance of another patent claiming
subject matter that is not patentably distinct from that under
appellate review. If an application is remanded by a panel of the Board
of Patent Appeals and Interferences and the remand is the last action
by a panel of the Board of Patent Appeals and Interferences prior to
the mailing of a notice of allowance under 35 U.S.C. 151 in the
application or if the Office reopens prosecution after a notice of
appeal has been filed but before any decision by the Board of Patent
Appeals and Interferences and issues an Office action under 35 U.S.C.
132 or notice of allowance under 35 U.S.C. 151, the remand or issuance
of an Office action under 35 U.S.C. 132 or notice of allowance under 35
U.S.C. 151 shall be
[[Page 18995]]
considered a decision in the review reversing an adverse determination
of patentability as that phrase is used in 35 U.S.C. 154(b)(2) as
amended by section 532(a) of the Uruguay Round Agreements Act, Public
Law 103-465, 108 Stat. 4809, 4983-85 (1994), and a final decision in
favor of the applicant under paragraph (c)(3) of this section. A remand
by a panel of the Board of Patent Appeals and Interferences shall not
be considered a decision in the review reversing an adverse
determination of patentability as provided in this paragraph if there
is filed a request for continued examination under 35 U.S.C. 132(b)
that was not first preceded by the mailing, after such remand, of at
least one of an action under 35 U.S.C. 132 or a notice of allowance
under 35 U.S.C. 151. A reopening of prosecution after a notice of
appeal has been filed shall not be considered a decision in the review
reversing an adverse determination as provided in this paragraph if
appellant files a request to withdraw the appeal, an amendment pursuant
to Sec. 41.33 of this chapter canceling all of the claims on appeal,
or a request for continued examination under 35 U.S.C. 132(b).
* * * * *
3. Section 1.702 is proposed to be amended by revising paragraph
(e) to read as follows:
Sec. 1.702 Grounds for adjustment of patent term due to examination
delay under the Patent Term Guarantee Act of 1999 (original
applications, other than designs, filed on or after May 29, 2000).
* * * * *
(e) Delays caused by successful appellate review. Subject to the
provisions of 35 U.S.C. 154(b) and this subpart, the term of an
original patent shall be adjusted if the issuance of the patent was
delayed due to review by the Board of Patent Appeals and Interferences
under 35 U.S.C. 134 or by a Federal court under 35 U.S.C. 141 or 145,
if the patent was issued under a decision in the review reversing an
adverse determination of patentability. If an application is remanded
by a panel of the Board of Patent Appeals and Interferences and the
remand is the last action by a panel of the Board of Patent Appeals and
Interferences prior to the mailing of a notice of allowance under 35
U.S.C. 151 in the application or if the Office reopens prosecution
after a notice of appeal has been filed but before any decision by the
Board of Patent Appeals and Interferences and issues an Office action
under 35 U.S.C. 132 or notice of allowance under 35 U.S.C. 151, the
remand or issuance of an Office action under 35 U.S.C. 132 or notice of
allowance under 35 U.S.C. 151 shall be considered a decision in the
review reversing an adverse determination of patentability as that
phrase is used in 35 U.S.C. 154(b)(1)(C)(iii), and a final decision in
favor of the applicant under Sec. 1.703(e). A remand by a panel of the
Board of Patent Appeals and Interferences shall not be considered a
decision in the review reversing an adverse determination of
patentability as provided in this paragraph if there is filed a request
for continued examination under 35 U.S.C. 132(b) that was not first
preceded by the mailing, after such remand, of at least one of an
action under 35 U.S.C. 132 or a notice of allowance under 35 U.S.C.
151. A reopening of prosecution after a notice of appeal has been filed
shall not be considered a decision in the review reversing an adverse
determination as provided in this paragraph if appellant files a
request to withdraw the appeal, an amendment pursuant to Sec. 41.33 of
this title canceling all of the claims on appeal, or a request for
continued examination under 35 U.S.C. 132(b).
* * * * *
4. Section 1.704 is amended by revising paragraph (d) to read as
follows:
Sec. 1.704 Reduction of period of adjustment of patent term.
* * * * *
(d)(1) A paper containing only an information disclosure statement
in compliance with Sec. Sec. 1.97 and 1.98 will not be considered a
failure to engage in reasonable efforts to conclude prosecution
(processing or examination) of the application under paragraphs (c)(6),
(c)(8), (c)(9), or (c)(10) of this section if it is accompanied by a
statement that each item of information contained in the information
disclosure statement:
(i) Was first cited in any communication from a patent office in a
counterpart foreign or international application or from the Office and
this communication was not received by any individual designated in
Sec. 1.56(c) more than thirty days prior to the filing of the
information disclosure statement; or
(ii) Is a communication that was issued by a patent office in a
counterpart foreign or international application or by the Office and
this communication was not received by any individual designated in
Sec. 1.56(c) more than thirty days prior to the filing of the
information disclosure statement.
(2) The thirty-day period set forth in paragraph (d)(1) of this
section is not extendable.
* * * * *
Teresa Stanek Rea,
Deputy Under Secretary of Commerce for Intellectual Property and Deputy
Director of the United States Patent and Trademark Office.
[FR Doc. 2011-8275 Filed 4-5-11; 8:45 am]
BILLING CODE 3510-16-P